09 September 2025
09 September 2025
The move positions Servier to expand its pipeline with assets that target rare indications.
Old and new-generation diabetes and obesity drugs such as Wegovy, Zepbound, Saxenda and Trulicity have made the list.
The true impacts of the price cuts will be seen by how GLP-1RA manufacturers adjust prices to remain competitive, market analysis suggests.
The funding will also expedite the progress of preclinical programmes and enhance the company's tech platforms.
Lilly’s BTK will continue to compete with AbbVie and J&J’s Imbruvica and BeOne Medicines’s Brukinsa.
Pipeline assets in development for CF draw attention to a limited range of MoAs.
The deal involves an initial payment of $65m from Braveheart to Hengrui, split equally between cash and equity in Braveheart.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
